3D Printing offers a better bone replacement

3D Printing Offers a Better Bone Replacement (ODTMag)
see all 3D Printing stories
To make a good framework for filling in missing bone, mix at least 30 percent pulverized natural bone with some special man-made plastic and create the needed shape with a 3D printer. That’s the recipe for success reported by researchers at The Johns Hopkins University in a paper published April 18 online in ACS Biomaterials Science & Engineering.
Each year, the Johns Hopkins scientists say, birth defects, trauma or surgery leave an estimated 200,000 people in need of replacement bones in the head or face. Historically, the best treatment required surgeons to remove part of a patient’s fibula (a leg bone that doesn’t bear much weight), cut it into the general shape needed and implant it in the right location. But, according to Warren Grayson, Ph.D., associate professor of biomedical engineering at the Johns Hopkins University School of Medicine and the report’s senior author, the procedure not only creates leg trauma but also falls short because the relatively straight fibula can’t be shaped to fit the subtle curves of the face very well.
That has led investigators to 3D printing, or so-called additive manufacturing, which creates three-dimensional objects from a digital computer file by piling on successive, ultrathin layers of materials. The process excels at making extremely precise structures—including anatomically accurate ones—from plastic, but “cells placed on plastic scaffolds need some instructional cues to become bone cells,” said Grayson. “The ideal scaffold is another piece of bone, but natural bones can’t usually be reshaped very precisely.”
In their experiments, Grayson and his team set out to make a composite material that would combine the strength and printability of plastic with the biological “information” contained in natural bone.
They began with polycaprolactone, or PCL, a biodegradable polyester used in making polyurethane that has been approved by the FDA for other clinical uses. “PCL melts at 80 to 100 degrees Celsius (176 to 212 Fahrenheit)—a lot lower than most plastics—so it’s a good one to mix with biological materials that can be damaged at higher temperatures,” said Ethan Nyberg, a graduate student on Grayson’s team.
PCL is also quite strong, but the team knew from previous studies that it doesn’t support the formation of new bone well. So they mixed it with increasing amounts of “bone powder,” made by pulverizing the porous bone inside cow knees after stripping it of cells.   “Bone powder contains structural proteins native to the body plus pro-bone growth factors that help immature stem cells mature into bone cells,” said Grayson. “It also adds roughness to the PCL, which helps the cells grip and reinforces the message of the growth factors.”
The first test for the composite materials was printability, Grayson says. Five, 30 and 70 percent bone powder blends performed well, but 85 percent bone powder had too little PCL “glue” to maintain clear lattice shapes and was dropped from future experiments. “It was like a chocolate chip cookie with too many chocolate chips,” said Nyberg.
To find out whether the scaffolds encourage bone formation, the researchers added human fat-derived stem cells taken during a liposuction procedure to scaffolds immersed in a nutritional broth lacking pro-bone ingredients.
After three weeks, cells grown on 70 percent bone powder scaffolds showed gene activity hundreds of times higher in three genes indicative of bone formation, compared to cells grown on pure PCL scaffolds. Cells on 30 percent bone powder scaffolds showed large but less impressive increases in the same genes.   After the scientists added the key ingredient beta-glycerophosphate to the cells’ broth to enable their enzymes to deposit calcium, the primary mineral in bone, the cells on 30 percent scaffolds produced about 30 percent more calcium per cell, while those on 70 percent scaffolds produced more than twice as much calcium per cell, compared to those on pure PCL scaffolds.
Finally, the team tested their scaffolds in mice with relatively large holes in their skull bones made experimentally. Without intervention, the bone wounds were too large to heal. Mice that got scaffold implants laden with stem cells had new bone growth within the hole over the 12 weeks of the experiment. And CT scans showed that at least 50 percent more bone grew in scaffolds containing 30 or 70 percent bone powder, compared to those with pure PCL.
“In the broth experiments, the 70 percent scaffold encouraged bone formation much better than the 30 percent scaffold,” said Grayson, “but the 30 percent scaffold is stronger. Since there wasn’t a difference between the two scaffolds in healing the mouse skulls, we are investigating further to figure out which blend is best overall.”
Although the use of “decellularized” cow bone has been FDA-approved for clinical use, in future studies, the researchers say, they hope to test bone powder made from human bone since it is more widely used clinically. They also want to experiment with the designs of the scaffolds’ interior to make it less geometric and more natural. And they plan to test additives that encourage new blood vessels to infiltrate the scaffolds, which will be necessary for thicker bone implants to survive. – See more at: http://www.odtmag.com/contents/view_breaking-news/2016-05-05/3d-printing-offers-a-better-bone-replacement/#sthash.5zjJNH3V.dpuf

Read More

Five MIS Spine news stories from the 2016 Spine Summit

Five news items to view for the latest in minimally invasive surgery for spine (Healio)
Spine Surgery Today spotlights five news items that focus on recently published research about minimally invasive surgery.
VIDEO: A look at challenges in lateral access to the lumbar spine
ORLANDO, Fla. — At the Spine Summit 2016: CNS/AANS Section on Disorders of the Spine and Peripheral Nerves Annual Meeting, Juan Uribe, MD, spoke about challenges in lateral access to the lumbar spine. He noted the best indicated patients for lateral access, the deformities best treated with the procedure as well as reasons to avoid this method of treatment.Watch video.
Stryker acquires SafeWire product portfolio for use in minimally invasive spine surgery
Stryker’s spine division announced it has acquired the SafeWire product portfolio which includes the Y-Wire guidewire and Tiger Jamshidi Needle products to be used for minimally invasive spine surgery, according to a Stryker press release. Read more.
Results of ‘awake’ TLIF showed no added complications vs MIS TLIF
ORLANDO, Fla. — Patients who underwent minimally invasive transforaminal lumbar interbody fusion under conscious sedation, in which no regional anesthetics or narcotics were used as part of a program to enhance recovery after surgery, sustained no intraoperative or postoperative complications. In addition, they had no signs of nonunion on follow-up imaging, according to a presenter, here. Read more.
Minimally invasive tubular microdiscectomy found effective for recurrent lumbar disc herniation
Researchers found minimally invasive tubular microdiscectomy can offer patients with recurrent lumbar disc herniation success rates comparable to those reported with other minimally invasive techniques. Read more.
 FDA approves additional clearance for Captiva Spine MIS pedicle screw system
Captiva Spine Inc. recently announced it received 510(k) clearance from the FDA for larger diameter screws within their TowerLOX MIS Pedicle Screw System and CapLOX II Pedicle Screw System.  Read more.

Read More

List of 14 publications on Hydroxyapatite and CaPO4

This article is for the biomaterials nerds who read OrthoStreams.
 
Below are links to 12 recent most comprehensive reviews on hydroxyapatite and other CaPO4.  A big thanks to Russian professor Sergey V. Dorozhkin PhD for providing this comprehensive list.
 
 
1. Calcium orthophosphates (CaPO4): occurrence and properties
http://link.springer.com/article/10.1007/s40204-015-0045-z2.Calcium orthophosphate bioceramics
http://www.sciencedirect.com/science/article/pii/S0272884215015291
3. Multiphasic calcium orthophosphate (CaPO4) bioceramics and their biomedical applications
http://www.sciencedirect.com/science/article/pii/S0272884216000936
4. Calcium orthophosphate deposits: preparation, properties and biomedical applications
http://www.sciencedirect.com/science/article/pii/S0928493115300837
5. Calcium orthophosphate-containing biocomposites and hybrid biomaterials for biomedical applications
http://www.mdpi.com/2079-4983/6/3/708
6. Calcium orthophosphates in dentistry
http://link.springer.com/article/10.1007/s10856-013-4898-1
7. A detailed history of calcium orthophosphates from 1770s till 1950
http://www.sciencedirect.com/science/article/pii/S0928493113002166
8. Nanodimensional and nanocrystalline calcium orthophosphates
http://academeresearchjournals.org/journal/ijcms/archive/june-2013-vol.-1-(6)
9. Calcium orthophosphate coatings on magnesium and its biodegradable alloys
http://www.sciencedirect.com/science/article/pii/S1742706114000786
10. Dissolution mechanism of calcium apatites in acids: a review of literature
http://www.wjgnet.com/2222-0682/abstract/v2/i1/1.htm
11. Amorphous calcium orthophosphates: nature, chemistry and biomedical applications
http://article.sapub.org/10.5923.j.ijmc.20120201.04.html
12. Self-setting calcium orthophosphate formulations
http://www.mdpi.com/2079-4983/4/4/209
In addition, there are 2 monographs of mine on CaPO4:
13. Calcium Orthophosphates: Applications in Nature, Biology, and Medicine [Hardcover]
http://www.amazon.com/Calcium-Orthophosphates-Applications-Biology-Medicine/dp/9814316628
14. Calcium Orthophosphate-Based Biocomposites and Hybrid Biomaterials [Paperback]
http://www.amazon.com/Orthophosphate-Based-Biocomposites-Biomaterials-Biomaterials-Properties-Production/dp/1608769410
Since nothing is perfect, any comments, suggestions, opinions, criticism, etc. are welcome.
Yours sincerely,
Sergey V. Dorozhkin
PS: Since various imperfections and even mistakes have been found in the previous versions of the reviews of mine, to get the best results, you are strongly advised to use and cite the aforementioned latest releases only.
PPS: See my profile at:
Academia.edu: http://dmv.academia.edu/SergeyDorozhkin
ACS ChemWorx: https://acschemworx.acs.org/app?x=/home#app?x=/e101&eId=e04b9bc270dc09a
EndNote – Web: http://www.myendnoteweb.com/EndNoteWeb.html?returnCode=ROUTER.Unauthorized&Init=Yes&SrcApp=CR&
Google scholar: http://scholar.google.ru/citations?user=dm8KISgAAAAJ&hl
LinkedIn: http://www.linkedin.com/profile/view?id=19349846&trk
Mendeley: http://www.mendeley.com/profiles/sergey-dorozhkin/
Microsoft Academic Search: http://academic.research.microsoft.com/Author/19801941
ORCID: http://orcid.org/0000-0002-8439-9527
ResearchGate: https://www.researchgate.net/profile/Sergey_Dorozhkin/
ResearcherID: H-1808-2011 http://www.researcherid.com/rid/H-1808-2011
———————————–
Sergey V. Dorozhkin
Kudrinskaja sq. 1 – 155
123242 Moscow D-242
Russia
Phone: (+7) 499-255-44-60
E-mail: [email protected]
———————————–

1. Calcium orthophosphate coatings on magnesium and its biodegradable alloys
http://www.sciencedirect.com/science/article/pii/S1742706114000786

2. Self-setting calcium orthophosphate formulations
http://www.mdpi.com/2079-4983/4/4/209

3. Calcium orthophosphates in dentistry
http://link.springer.com/article/10.1007/s10856-013-4898-1?wt_mc

4. Calcium orthophosphate-based bioceramics
http://www.mdpi.com/1996-1944/6/9/3840/

5. A detailed history of calcium orthophosphates from 1770s till 1950
http://www.sciencedirect.com/science/article/pii/S0928493113002166

6. Nanodimensional and nanocrystalline calcium orthophosphates
http://academeresearchjournals.org/journal/ijcms/archive/june-2013-vol.-1-(6)7. Calcium orthophosphate coatings, films and layers
http://www.progressbiomaterials.com/content/1/1/18. Dissolution mechanism of calcium apatites in acids: a review of literature
http://www.wjgnet.com/2222-0682/abstract/v2/i1/1.htm9. Amorphous calcium orthophosphates: nature, chemistry and biomedical applications
http://article.sapub.org/10.5923.j.ijmc.20120201.04.html10. Calcium orthophosphates: occurrence, properties, biomineralization, pathological calcification and biomimetic applications
http://www.tandfonline.com/doi/full/10.4161/biom.1879011. Biocomposites and hybrid biomaterials based on calcium orthophosphates
http://www.tandfonline.com/doi/full/10.4161/biom.1.1.16782
12. Biphasic, triphasic and multiphasic calcium orthophosphates
http://www.sciencedirect.com/science/article/pii/S1742706111003874
 
In addition, there are 2 monographs from Sergey V. Dorozhkin on CaPO4:
13. Calcium Orthophosphates: Applications in Nature, Biology, and Medicine [Hardcover]
http://amzn.to/1cqoNYZ
14. Calcium Orthophosphate-Based Biocomposites and Hybrid Biomaterials [Paperback]
http://amzn.to/1Ikj96i

Read More

Materialise CEO Calls for Common Approach in Measuring Clinical Evidence for Medical 3D Printing

Materialise CEO Calls for Common Approach in Measuring Clinical Evidence for Medical 3D Printing (press release)
For more… read my interview with Materialize CEO
Read list of 3D Printers in Orthopedics

CEO states that an evidence-based approach is necessary for medical 3D printing to gain the regulatory acceptance needed to be able to help more patients and save lives.
Orlando, Florida – May 5, 2016. Fried Vancraen, CEO of Materialise NV (Nasdaq: MTLS), the leading provider of Additive Manufacturing software and sophisticated 3D Printing solutions in the medical and industrial markets, calls upon industry stakeholders to come to an agreement for a common standard for measuring the clinical, economical and patient benefits of medical 3D printing in delivering better patient outcomes. Materialise will be leading this on-going initiative as the founding sponsor of the Building Evidence for 3D Printing Applications in Medicine event hosted by SME.
It is becoming increasingly clear that 3D printed anatomical models, guides and implants will be part of the future of patient treatment, for more than just complex procedures. But, unlike the mass-produced medical device industry, adoption of 3D printing needs more generally accepted measurement standards. The application of consistent and complete evidence- gathering methodologies across the industry could significantly foster the adoption of 3D Printing application in the healthcare sector.
A unified initiative addressing the clinical measurement challenge will further enhance the healthcare industry’s confidence in the clinical benefits of medical 3D Printing. A set of globally accepted guidelines adopted by the major medical 3D printing industry players will convince key stakeholders like physicians, hospitals and policy makers to accelerate adoption of the technology. What is more, governmental bodies and insurance companies are more likely to be open to including medical 3D printing as part of their approved list of medical procedures and devices, leaving patients with the opportunity to leverage the best solutions that technology has to offer for their care.
‘A call to apply evidence-based medicine’
“There have been several initiatives aimed at properly measuring and validating the clinical benefits of medical 3D Printing, but all have suffered from a lack of coordination and agreed- upon research methodologies,” stated Fried Vancraen, CEO of Materialise NV. “The fact is, we can only be successful if we take an evidence-based approach across the industry, acting in concert with a set of protocols, methodologies and measurement guidelines. With the proper scientific rigor, our ambition of gaining widespread acceptance of medical 3D Printing will be realized more swiftly, and the patients whom we aim to serve will benefit the most.”
‘Materialise will continue to lead by example’
Meeting the rigorous criteria of evidence-based medicine would not only accelerate the adoption of medical 3D Printing but it would also benefit the lives of so many patients who have no access to the amazing health benefits afforded by medical 3D Printing today. Materialise is committing to take a leadership role in what has to be an industry-wide initiative to begin studying and designing a new evidence-based approach that will factor in all key perspectives: economical, clinical, engineering and patient.

“The goal is nothing short of establishing the groundwork for producing solid clinical evidence on 3D printed medical applications, including anatomical models, patient-specific guides and implants,” added Fried Vancraen. “Anything short of this will slow down the wonders of medical 3D Printing from becoming available to patients and medical professionals the world over.”
Be part of the initiative
Join Materialise as the founding sponsor at the Building Evidence for 3D Printing Applications in Medicine event hosted by SME, following the RAPID Conference, an annual 3D printing and additive manufacturing event, on May 19-20 in Orlando, Florida. For more information and to register, please visit www.materialise.com/building-evidence-for-medical-3d-printing or contact Jessica Morrison at 734.259.6685.
About Materialise
Materialise incorporates more than 25 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.
Pictures:
A high-res picture of Mr. Vancraen can be found here: http://bit.ly/1SZPHaf
Press contact:
Virginia Goble
Marketing and Strategy
Mobile: (248) 921.5000
Email: [email protected] Twitter: @MaterialiseNV
Visit: www.materialise.com

Read More

The new FDA Commissioner says "It' all about the pain"

NEW FDA COMMISSIONER: “IT’S ABOUT THE PAIN” (Orthopedics This Week)
If you’re in the business or profession of addressing pain, you’ve got the attention of the new FDA Commissioner, Robert Califf, M.D.
On March 30, 2016, Califf wrote in his first agency blog posting that the agency has an overarching “clear, realistic, and focused sense of priorities,” with pain and the “present epidemic of opioid overdose” a specific critical issue on his front burner.
The Commissioner writes that the vast of majority of decisions made by the agency are made possible by “a system sustained by professionalism and a well-earned reputation for high-quality and impartial judgments—despite the fact that many decisions must ultimately disappoint (or at least not fully satisfy) one or more constituencies.”
He notes that dramatic advances in biotechnology and information sciences, as well as continuously accelerating trends toward globalization, are ushering in an era of rapid change.
High Quality Evidence
“We must do everything possible to rapidly adapt our national and global systems of evidence generation to meet the challenges and opportunities presented by technological advances. What does this mean? I’ve noticed that when high-quality evidence is available, FDA’s scientific decision making is often straightforward. But it can be particularly challenging for the Agency when it must make scientific decisions in the absence of optimal information. In such cases, opinions may carry greater weight, and there can be an increased likelihood of dissension both inside and outside of FDA, as well as a greater risk that we may fail to most fully protect or advance the welfare of patients and the public.”
He’s especially focused on biomedical science, which he says is nearing a tipping point where the amount of high-quality evidence available to support our decisions is likely to increase exponentially.
Big Data
Big data is also on his radar.
“As a nation, we have invested over $50 billion to provide an electronic health record (EHR) for almost every American. Further, computational storage capacity and analytical power are increasing by orders of magnitude from year to year. At the same time, the advent and wide diffusion of social media are enabling direct communication with patients and consumers on an unprecedented scale. When projects such as Sentinel and the National Medical Device Evaluation System are linked with the many complementary initiatives under way at our sister agencies and at organizations outside of the government, we can (and I believe in short order will!) build a robust foundation for a system in which both private and public sectors can produce much more useful knowledge at a fraction of the cost such efforts have previously required. Indeed, a major function of FDA is to support the continued development of an effective system for evidence generation, so that the private and academic sectors can make it happen.”
The Commissioner is likely a lame-duck, as a new president in 2017 is likely to appoint his or her own choice to the politically appointed job. But the Commissioner’s observations are likely deeply embedded in the agency’s internal bureaucratic agenda and worth taking seriously.

Read More

Technology, Startup News, Career Advice & More

Archives

Pin It on Pinterest

Menu